Veracyte (VCYT) said results from an independent Phase 3 trial show its Prosigna Breast Risk of Recurrence test can safely guide adjuvant chemotherapy decisions for patients with early-stage, ER-positive, HER2-negative breast cancer.

The study, led by University College London, enrolled 4,429 patients and had a median follow-up of four years, Veracyte said Friday in a statement. Investigators reported that Prosigna provided Level 1A evidence, demonstrating the test can accurately predict chemotherapy benefit and support safe treatment de-escalation across high-risk groups.

The results will be presented Saturday at the annual meeting of the American Society of Clinical Oncology.

Price: 46.32, Change: -1.67, Percent Change: -3.48